Projects per year
The Wooldridge Clinical T cell lab group which is led by Professor Linda Wooldridge has three main areas of interest, these include;
1. CD8+ T cell mediated conditions such as autoimmunity and T cell leukaemia.
2. Targeting the CD8 co-receptor for therapeutic benefit.
CD8 has a potent ability to tune the antigen specific immune response. As such, we ae investigating the possiblity that targetting CD8 can be used to:
- Block the pathogenic CD8+ T cell attack observed in autoimmune disease and transplant rejection (Mathew Clement).
- Enhance CD8+ T cell immunity especially in a cancer setting where responses are suboptimal (Tamsin Williams).
Unique Recognition System
CD8+ T cells recognize antigenic determinants in the form of short peptides derived from endogenous peptides bound to MHC class I (pMHCI). CD8+ T cell recognition of pMHCI involves the binding of two receptors (T cell receptor; TCR and CD8) to a single ligand (pMHCI), a modus operandi that is unique to ab T cell biology. Therefore CD8+ T cell activation involves two key interactions:
- The TCR/pMHCI interaction: determines antigen specificity. Promiscuity is a characteristic feature of this interaction and it is essential for effective immunity.
- The pMHCI/CD8 interaction: has a potent ability to tune the antigen specific immune response by a number of different mechanisms.
Figure 1: Interaction between TCR MHCI and CD8
We are interested in understanding both of these interactions and how to manipulate them for therapeutic benefit.
3. Development of technology to study the TCR and CD8 co-receptor.
Our overall aim is to understand the mechanisms of CD8+ T-cell mediated disease and use this knowledge to develop novel therapeutic reagents.
Further information about Professor Linda Wooldridge can be found here.
- 1 Similar Profiles
Dive into details
Select a country/territory to view shared publications and projects
- 3 Finished
UKCiC Characterization of COVID-19 long-term immunity (R101755-COA funding)
1/10/20 → 30/09/21
(CLOSED) 8055 BVS UK CIC Characterisation of COVID-19 long-term immunity (NCS_1) WP3
1/10/20 → 31/03/21
EN_ACTI2NG: Linda Wooldridge
1/01/17 → 30/04/21
T Cells: Ready and waiting to goWooldridge, L. & Rivino, L., 6 Jan 2023, In: eLife. 12, 3 p., e85080.
Research output: Contribution to journal › Comment/debate (Academic Journal)Open AccessFile8 Downloads (Pure)
Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2Halliday, A., Long, A. E., Baum, H. E., Thomas, A., Shelley, K. L., Oliver, E. H., Gupta, K., Francis, O., Kavanagh Williamson, M., Di Bartolo, N. D., Randell, M. J., Ben Khoud, Y., Kelland, I., Mortimer, G. L. M., Ball, O. E., Plumptre, C., Chandler, M. A., Obst, U., Secchi, M., Piemonti, L., & 27 others, 9 Nov 2022, In: Frontiers in Immunology. 13, 20 p., 968317.
Research output: Contribution to journal › Article (Academic Journal) › peer-reviewOpen AccessFile13 Downloads (Pure)
Hyperactive immature state and differential CXCR2 expression of neutrophils in severe COVID-19Rice, C. M., Lewis, P., Ponce-Garcia, F. M., Gibbs, W., Groves, S., Cela, D., Hamilton, F., Arnold, D., Hyams, C., Oliver, E., Barr, R., Goenka, A., Davidson, A., Wooldridge, L., Finn, A., Rivino, L. & Amulic, B., 13 Dec 2022, (E-pub ahead of print) In: Life Science Alliance. 6, 2, p. 1-13 e202201658.
Research output: Contribution to journal › Article (Academic Journal) › peer-reviewOpen AccessFile2 Downloads (Pure)